Fremanezumab
Product Specifications
Target
CGRP Receptor
Related Pathways
GPCR/G Protein|||Neuroscience
Purity
0.976
Bioactivity
Fremanezumab (TEV-48125) is a humanised monoclonal antibody targeting CGRP, capable of neutralising human (IC50=7.94 nM), mouse (IC50=19.6 nM) and rat CGRP, and is indicated for the prevention of migraine. Fremanezumab inhibits CGRP's vasodilatory effects in the basilar artery constriction segment and suppresses activation of A-? and high-threshold (HT) neurons in the meningeal nociceptive system triggered by cortical spreading depression (CSD) in rats. In vitro, Fremanezumab counteracts CGRP's immunosuppressive effects on microglia and lymphocytes.
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Product Datasheet
https://www.targetmol.com/attachment/DataSheet/64416316517253250/T76680
CAS Number
1655501-53-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1102337-01 0.02 mg (E-Coli)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details MBS1102337-02 0.1 mg (E-Coli)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details 
MBS1102337-03 0.02 mg (Yeast)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details 
MBS1102337-04 0.1 mg (Yeast)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details MBS1102337-05 0.02 mg (Baculovirus)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details MBS1102337-06 1 mg (E-Coli)
Recombinant Bacillus cereus Small, acid-soluble spore protein O (sspO)
Ask
View Details